<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04150172</url>
  </required_header>
  <id_info>
    <org_study_id>037-402-00035</org_study_id>
    <nct_id>NCT04150172</nct_id>
  </id_info>
  <brief_title>To Evaluate Pharmacokinetics and Safety of Two Different Formulation of Rebamipide in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Open Label, Multiple Dose, Crossover Study to Compare the Safety and Pharmacokinetics Between &quot;Rebamipide Sustained Release (SR) 150mg&quot; and &quot;Rebamipide Immediate Release (IR) 100mg&quot; in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open label, multiple dose, crossover study to compare the safety and
      Pharmacokinetics (PKs) between two rebamipide formulations after multiple oral doses of
      &quot;rebamipide SR 150 mg&quot; and &quot;rebamipide IR 100 mg&quot; in healthy adult volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 22, 2019</start_date>
  <completion_date type="Actual">May 10, 2019</completion_date>
  <primary_completion_date type="Actual">May 1, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>From Period1/ Day1 to Period2/Day9</time_frame>
    <description>Peak Plasma Concentration of Rebamipide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of Rebamipide</measure>
    <time_frame>From Period1/ Day1 to Period2/Day9</time_frame>
    <description>Area Under the plasma concentration versus time curve last of Rebamipide</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>t1/2 β of Rebamipide</measure>
    <time_frame>From Period1/ Day1 to Period2/Day9</time_frame>
    <description>Time taken for half the initial dose of Rebamipide administered to be eliminated from the body</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Rebamipide</measure>
    <time_frame>From Period1/ Day1 to Period2/Day9</time_frame>
    <description>Time at which the Cmax of Rebamipide is observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Rebamipide</measure>
    <time_frame>From Period1/ Day1 to Period2/Day9</time_frame>
    <description>Area Under the plasma concentration versus time curve inifinite of Rebamipide</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Sequence A (RT)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>[Sequence A (RT) &amp; Sequence B (TR)] to receive the Investigational Product (IP) by the sequence in each period:
Rebamipide IR 100 mg (R): Take one tablet each at 9 am, 3 pm and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours.
Rebamipide SR 150 mg (T): Take one tablet each at 9 am and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B (TR)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>[Sequence A (RT) &amp; Sequence B (TR)] to receive the Investigational Product (IP) by the sequence in each period:
Rebamipide IR 100 mg (R): Take one tablet each at 9 am, 3 pm and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours.
Rebamipide SR 150 mg (T): Take one tablet each at 9 am and 9 pm on 1d (8d) with 150 mL of water. For 9 am dose, take under the fasting condition for ≥10 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebamipide SR 150mg</intervention_name>
    <description>Test drug</description>
    <arm_group_label>Sequence A (RT)</arm_group_label>
    <arm_group_label>Sequence B (TR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebamipide IR 100mg</intervention_name>
    <description>Reference Drug</description>
    <arm_group_label>Sequence A (RT)</arm_group_label>
    <arm_group_label>Sequence B (TR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects who give consent to voluntary participation by signing the informed consent
             form

          2. Healthy adult males aged ≥19 and ≤45 years at screening

          3. Subjects with weight ≥50 kg AND body mass index (BMI) ≥18.0 and ≤27.0

        Exclusion Criteria:

          1. Subjects with hypersensitivity to the active ingredient of the IP or other anti-ulcer
             agents or history of clinically significant hypersensitivity

          2. Subjects with any past history of gastrointestinal diseases which can affect the
             absorption of the IP

          3. Subjects who have participated in other clinical trial and received any other
             investigational products within 3 months before the expected date of IP administration

          4. Subjects who have taken any inducers or inhibitors of drug metabolism enzyme

          5. Subjects who have been on diets that may affect the absorption, distribution,
             metabolism, and excretion of a drug

          6. Subjects who donated whole blood within 2 months or underwent apheresis within 1 month
             prior to obtaining informed consent or who did not agree to prohibit blood donation

          7. Smokers who have smoked &gt;10 cigarettes per day within the last 6 months

          8. Subjects with any positive result on HBsAg, hepatitis C virus (HCV) Ab, HIV Ab, and
             venereal disease research laboratory (VDRL) tests
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHA Bundang Medical Center, CHA University</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <zip>13496</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rebamipide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

